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Abstract
Background: The treatment options for high-risk prostate cancer are either radical prostatectomy or radiotherapy/
brachytherapy depending on the patients’ prognosis. In older men with multiple comorbidities, radiotherapy with
androgen deprivation therapy is an attractive option. Common side effects of androgen deprivation therapy include
hot flushes, tiredness, increased risk of fractures, increased risk of metabolic disorders, coronary heart disease, and
psychological effects. This case highlights the potential side effect of lipodystrophy secondary to leuprolide acetate
injections. To the best of our knowledge, this is the first reported case of such an instance.
Case presentation: In this case report, we describe a 70-year-old white man with prostate-specific antigen of 1.8
ng/mL, clinical stage T2bN0M0, Gleason 4+5=9 prostate cancer who developed an unusual side effect from
leuprolide acetate as part of his androgen deprivation therapy. Approximately 2 months after the initial 3-monthly
injection of leuprolide acetate (Eligard 22.5 mg) our patient developed abnormal lipid deposition particularly in his
deltoid and abdominal region. His upper limb mobility gradually became compromised due to the size of these
abnormal fat depositions. He had liposuction to correct this lipodystrophy and had a good functional outcome and
cosmesis from the procedure.
Conclusions: To the best of our knowledge, this is the first reported case of lipodystrophy secondary to leuprolide
acetate injections. Leuprolide acetate in commonly used as one of the gonadotrophin-releasing hormone agonists
and thus we should be mindful of the potential effect of producing lipodystrophy, especially in patients with
cirrhosis, and to watch for any signs and symptoms as appropriate. The implication of this potential side effect
poses difficult management strategies for such patients, and second-line alternatives such as chemotherapy may
need to be considered.
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Background
The treatment of prostate cancer depends on the risk
stratification and staging of the patient. Initial evaluation of
a patient with suspected prostate cancer includes a detailed
history, digital rectal examination, pre-treatment serum
prostate-specific antigen (PSA), and Gleason score from the
initial prostate biopsy. Imaging studies that are used include
radionuclide bone scan and computed tomography (CT)/
magnetic resonance imaging (MRI) of the abdomen and
pelvis to look for nodal and metastatic involvement. With
those findings patients are staged according to American
Joint Committee on Cancer (AJCC)/Union for Inter-
national Cancer Control (UICC) classifications [1, 2].
Based on their staging workup we can stratify patients
into various classifications as suggested by the National
Comprehensive Cancer Network (NCCN) [3]. Patients
who are in the high-risk group are offered either radical
prostatectomy with pelvic lymph node dissection or
radiotherapy and androgen deprivation therapy with or
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without the addition of brachytherapy based on each pa-
tient’s life expectancy.
Eligard (leuprolide acetate also known as leuprorelin) is
generally well tolerated, with the most common adverse
event being flushing and injection site erythema [4]. It has
not been reported to produce lipodystrophy. Lipodystro-
phy can either result from congenital disorders or ac-
quired conditions. Lipodystrophy is most commonly
associated with anti-retroviral medications in the treat-
ment of human immunodeficiency virus (HIV) infections
[5]. In this case report, we discuss an unreported side ef-
fect of lipodystrophy from leuprorelin injection as part of
a patient’s androgen deprivation therapy.
Case presentation
A 70-year-old white man presented with a history of lower
urinary tract symptoms suggestive of prostatic enlarge-
ment. His background history included appendicectomy,
diverticulitis, hypertension, and past heavy alcohol intake.
He denied any significant family history. On examination,
his prostate was found to be smooth and mildly enlarged.
At this stage his PSA was measured at 1.8. Within 2
months it nearly doubled to 3.2 and a hard nodule was
now felt on the right side of his prostate. He had a pros-
tate biopsy under ultrasound guidance 3 months later and
was found to have adenocarcinoma with Gleason score of
9 (5+4). Of the cores examined, 11 out of 17 were positive
for adenocarcinoma. His prostate volume was 27 cc.
He underwent staging with a bone scan and CT of his
chest, abdomen, and pelvis. There was no evidence of
metastatic disease but there was evidence suggestive of liver
cirrhosis on CT. After lengthy discussion with his urologist
and radiation oncologist he proceeded with external beam
radiotherapy with neoadjuvant and adjuvant androgen
deprivation therapy. He received 76 Gy in 38 fractions
using a conformal technique within 8 months of the pros-
tate biopsy. He was also commenced on 3-monthly Eligard
(leuprolide acetate also known as leuprorelin) subcutaneous
injections (22.5 mg) over his lower abdomen for androgen
deprivation.
He started to note the development of abnormal swelling
over his deltoids to the extent that it was interfering with his
activities of daily living. The swelling was so large that he
was unable to wear some shirts and he was unable to abduct
and forward flex his shoulder joint which made reaching
over his head to retrieve items from cupboards very difficult.
He noticed these swellings over the 2 months post his first
Eligard (leuprolide acetate also known as leuprorelin) injec-
tion (Fig. 1); however, this was not raised until one of his
radiotherapy sessions. On examination he was noted to have
a raised soft mass over his deltoids bilaterally measuring ap-
proximately 10 cm in diameter. His leuprolide injection was
ceased. During the period of leuprolide treatment (9
months) he did not have any regimen change to his regular
medications. His PSA and testosterone levels at the end of
his radiotherapy were 0.03 ng/mL and 1 nmol/L respect-
ively. Upon stopping the leuprolide injections he did note
his hot flushes symptom had improved. A thorax CT was
performed and confirmed these masses to be adipose tissue.
He went to see a plastic surgeon who performed liposuction
of the lipodystrophies on his deltoid regions. This had a
good effect at 6 months postoperative follow up (Fig. 2).
On his most recent follow up, he unfortunately showed
signs of clinical relapse with a rising PSA from 0.75 ng/mL
and testosterone of 26.8 nmol/L (January 2014) to a PSA of
24 ng/mL and testosterone level of 34.1 nmol/L (September
2014) as well as evidence of bone metastases on a repeat
bone scan. He was then recommenced on goserelin acetate
10.8 mg 3-monthly subcutaneous injection as a single agent
for further treatment which has so far seemed successful.
Discussion
The use of luteinizing hormone-releasing hormone (LHRH)
agonists is not only limited to advance prostate cancer.
They are commonly used in fertility treatments, endometri-
osis, precocious puberty, uterine fibroids, and hirsutism [6].
Fig. 1 Before liposuction, 2 months post-initial leuprolide acetate injection
Chang and Bucci Journal of Medical Case Reports  (2016) 10:323 Page 2 of 4
For fertility treatments, LHRH agonists are used in assisted
reproduction technology to produce with a higher clinical
pregnancy rate per cycle [7]. For treatment of pain from
endometriosis, LHRH analogs produce a downregulation of
the pituitary glands and thus result in ovarian suppression.
This has been reported to be effective in upwards of 85 %
of women [8]. Precocious puberty can also be treated by
LHRH agonists and is known to be well tolerated and ef-
fective in suppressing luteinizing and follicle-stimulating
hormones [9]. By the same principles as mentioned above,
LHRH agonists can also be used in treating leiomyomas
and hirsutism [10, 11]. The side effects for applications
discussed above are the result of low estrogen level;
symptoms such as hot flushes, tiredness, vagina dryness,
and decreased libido are common. The most severe one is
probably LHRH agonists’ effect on bone loss [12]. However
there has been no mention of any lipodystrophy associated
with LHRH agonists use in the literature.
It is interesting to note that lipodystrophy can also be seen
in patients with HIV. The mechanism for this has not yet
been proven but one theory suggests that it is related to HIV
type 1 protease inhibitors and nucleoside reverse transcript-
ase inhibitors such as stavudine and zidovudine [13, 14].
Although the mechanism for the lipodystrophy in our
patient is not clear, we postulate that due to the androgen
surge that is associated with LHRH agonists such as leupror-
elin [15], it created an environment where excess testoster-
one is available for the conversion to estrogen by aromatase.
In a normal healthy liver there is usually little to no aroma-
tase activity in the liver; however, in cirrhotic livers (such as
in our patient from his previous heavy alcohol intake) it has
been shown that there is increased aromatase activity and
estrogen formation [16]. It is thought that this excess estro-
gen level is the cause for the abnormal fat deposition.
Conclusions
In this case report we discuss an uncommon side effect
from leuprolide acetate injections for the treatment of
prostate cancer. To the best of our knowledge this is the
first reported case of lipodystrophy secondary to leupro-
lide acetate injections. Leuprolide acetate is commonly
used as one of the gonadotrophin-releasing hormone
agonists and thus we should be mindful of the potential
effect of producing lipodystrophy, especially in patients
with cirrhosis, and to watch for any signs and symptoms
as appropriate. The implication of this potential side effect
poses difficult management strategies for such patients,
and second-line alternatives such as chemotherapy may
need to be considered.
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